Rick Kendall

Based in California, Dr Rick Kendall is vice president of research at Kite Pharma and is responsible for the company’s research pipeline and developing CAR-T technology.
Dr Kendall was executive director of Oncology Research at Amgen, where he directed a group of 90+ scientists, and was responsible for the development of the Amgen cancer franchise strategy aligning research with other functions including Chemistry, Protein Sciences, Medical Translational Sciences, Development and Commercial. Results included 17 clinical candidate molecules made up of 9 small molecules and 8 protein therapeutics. Dr Kendall holds an associate adjunct professor position in the Department of Molecular, Cellular and Developmental Biology, at the University of California at Santa Barbara. Prior to joining the board of Phylogica in April 2017, Dr Kendall has consulted on the development of the company’s assets including the iMyc oncology program and Functional Penetrating Phylomer (FPP) intracellular drug delivery technology.